Agilent Technologies
A · NYSE · Health Care
+$0.15 today
- Mkt cap $38.25B
- P/E 27.2
- Day $133.27 – $137.69
Confidence
High conviction
The read
Agilent Technologies Q2 EPS estimate $1.40; actual EPS not yet reported; stock modestly up post-earnings
Agilent reported Q2 earnings with EPS estimate at $1.40 but actual EPS is unavailable. The stock showed a slight 0.11% increase post-earnings. Analysts remain mostly bullish with a consensus target price of $158.62, implying 19.1% upside. Institutional ownership is high at 93.2%, and fundamentals show strong capital efficiency and margin strength. The company’s forward P/E is richer than sector average, reflecting growth expectations. Investors should monitor upcoming full-year guidance and actual EPS release for confirmation of growth sustainability.
Confidence note: High confidence due to strong fundamental metrics and analyst consensus, tempered by missing actual EPS data.
What happened
Earnings print
Guidance
Price reaction
Street narrative
So what
What changed
What the market is pricing
Fundamental takeaway
Next 30–90 days
Actual EPS beats estimate and full-year guidance is raised, confirming margin expansion and growth.
- boltRelease of actual Q2 EPS exceeding $1.40 estimate
- boltFull-year guidance raised above current analyst expectations
Actual EPS meets estimate and guidance remains stable, supporting current valuation and growth expectations.
- boltActual EPS close to $1.40 estimate
- boltGuidance unchanged or consistent with analyst consensus
Actual EPS misses estimate and guidance is lowered, pressuring valuation and momentum.
- boltActual EPS below $1.40 estimate
- boltGuidance lowered or cautious commentary on growth prospects
What to do
If you hold it
If you're watching
Keep on your radar
- Release date and value of actual Q2 EPS
- Full-year guidance update timing and content
- Institutional ownership changes over next quarter
- Stock RSI and momentum indicators for overbought signals